Cholera Vaccine Market Global Share, Trend Analysis and Forecast Report

Cholera Vaccine Market Report, By Product (Dukoral, Shanchol and Vaxchora) and Geography - Global Market Share, Trend Analysis & Forecast , 2019 - 2028

Report Code : hc2007 | Publish Date : Upcoming | Industry : Healthcare | Geography : Global


Cholera is a diarrheal illness caused by an infection of the intestine by the Vibrio cholerae bacterium. In about 80% of cholera infections, the person have no symptoms or very mild symptoms. However, about 20% of people with symptoms experience profuse watery diarrhea, vomiting, and leg cramps. Cholera is transmitted by ingesting food or water contaminated with V. cholerae. The contamination occurs when fecal matter from a sick person comes into contact with food or water supplies. Moreover, in areas with poor environmental management and overcrowding, the risk of cholera increases dramatically. Several oral cholera vaccines are available globally. Furthermore, the vaccines provide about 65%-85% protection from clinically significant cholera for a period of time from 4 months after vaccination to up to 5 years after vaccination, depending on the vaccine. Additionally, the FDA recently approved a single-dose live oral cholera vaccine called Vaxchora (lyophilized CVD 103-HgR) in the United States. According to WHO, in 2016, 132 121 cholera cases and 2420 deaths were reported worldwide.

Cholera Vaccine Market Segmental Overview

The cholera vaccine market is segmented by Product and geography. 

Cholera Vaccine Market by Product

The various product of the cholera vaccine market are covered in the report such as dukoral, shanchol and vaxchora. Among these, the dukoral segment dominated the cholera vaccine market in 2018. Because it is the only vaccine that provides protection against diarrhea caused by heat-labile-toxin-producing E. coli. Whereas, the vaxchora is expected to be the fastest growing segment during the forecast period.

Cholera Vaccine Market by Geography

The cholera vaccine market report is studied across the key countries of North America, Europe, Asia Pacific, Latin America and Middle East & Africa. The Middle East & Africa regions dominated the cholera vaccine market in 2018, followed by Asia Pacific. Owing to high number of cholera patients in this region. Thus, the sales of cholera vaccines are high in the region. Moreover, according to the WHO, in 2016, cholera cases out of worldwide 54% were from Africa and 13% from Asia.

Cholera Vaccine Market Key Players 

Some of the key participants in the cholera vaccine market are Shantha Biotechnics Private Limited, Valneva SE, PaxVax, Inc., Astellas Pharma, Inc., Merck & Co., Inc., GlaxoSmithKline plc (GSK), Pfizer, Inc., Takeda Pharmaceutical Co., Ltd., Emergent BioSolutions, Inc., AstraZeneca and Mitsubishi Tanabe Pharma Corporation. The majority of companies are aiming towards product launches, mergers & acquisitions and research & development to enhance their visibility in the high competitive arena of the cholera vaccine market. 

Cholera Vaccine Market Developments  

January 2015, European biotechnology company Valneva SE acquired Crucell Sweden AB and all assets, licenses and privileges related to Dukoral 1, a vaccine against cholera and traveler’s diarrhea caused by ETEC. The total transaction consideration amounts to EUR 45 million.

October 2016, PaxVax, Inc. announced that Vaxchora is now available in the United States (U.S.) as the country’s only vaccine for protection against cholera, a highly contagious intestinal diarrheal infection that can cause death in less than 24 hours if left untreated.

February 2018, Shantha Biotechnics, an affiliate of Sanofi Pasteur, has received approval from the World Health Organisation (WHO) for Shanchol, its oral cholera vaccine. The approval is for use at temperatures as high as 40°C for up to 14 days, immediately prior to administration, among others.

The cholera vaccine market is segmented by Product and geography. The various product of the cholera vaccine market are covered in the report such as dukoral, shanchol and vaxchora. Among these, the dukoral segment dominated the cholera vaccine market in 2018. Because it is the only vaccine that provides protection against diarrhea caused by heat-labile-toxin-producing E. coli. Whereas, the vaxchora is expected to be the fastest growing segment during the forecast period.

The cholera vaccine market report is studied across the key countries of North America, Europe, Asia Pacific, Latin America and Middle East & Africa. The Middle East & Africa regions dominated the cholera vaccine market in 2018, followed by Asia Pacific. Owing to high number of cholera patients in this region. Thus, the sales of cholera vaccines are high in the region. Moreover, according to the WHO, in 2016, cholera cases out of worldwide 54% were from Africa and 13% from Asia.


Why to buy this report:

  • The report offers changing market dynamics in the cholera vaccine market, presenting historical, current and projected market size in terms of value (USD Million)
  • The research study provides an in-depth analysis of the industry value chain focusing on the peer and parent markets of cholera vaccine
  • It presents a comprehensive assessment of geographical regions exhibiting promising growth, potential and niche segments, and a neutral perspective on the cholera vaccine market performance 
  • The report also offers strategic recommendations in key business segments based on the market estimations and competitive landscape, mapping the key common trends of cholera vaccine market